The Ella Institute for Treatment and Research of Melanoma
The Ella Institute offers a wide range of the most advanced oncology treatment and diagnostic techniques in melanoma and skin cancer as well as state of the art research laboratories in immunotherapy of cancer.
The institute is headed by Prof. Jacob Schachter- Deputy Director Oncology Department at the Sheba Medical Center, Senior lecturer at the Tel Aviv University, Head of the Israeli forum of Melanoma. The Institute is part of the Oncology Division, Prof Raphael Catane - chairman, and The Cancer Research Center, Prof Gidi Rechavi - Chairman, at the Sheba Medical Center, Tel Hashomer, Israel.
Treatment of Metastatic Melanoma: The Ella Institute offers a new experimental treatment for patients with metastatic melanoma. This innovative treatment was developed in the United States at the National Cancer Institute (NCI) and is based on adoptive immunotherapy of anti-cancer lymphocytes. The Sheba Medical Center is the only hospital out of the US which offers this innovative treatment, and applied it already successfully in advanced melanoma patients, which failed all other treatments. The treatment is based on amplifying and adoptive transfer of the patient's own white blood cells (TIL - tumor infiltrating lymphocytes), which can react against the tumor tissue, together with myeloablative chemotherapy and interluikin 2. Clinical results of the treatment in Sheba were published recently.
The Ella Institute also offers advanced bio-chemo treatment such as High dose IL2 and Interferone, combined with chemotherapy to metastatic melanoma patients.
For melanoma patients with high risk for recurrence, the Ella Institute offers advanced adjuvant treatments such as high dose interferon alpha and other modalities.
A world expert scientific team is leading research and development programs for anti-cancer modalities in state of the art research laboratories, as well as GTP (good tissue culture practice) laboratory, equipped for translational and clinical production of cellular therapies.
